anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading, residual acid is quenched with a quenching agent that is base permeable at low temperatures. The residual aciditiy is thus reduced and chemical stability (e.g. against hydrolysis) is enhanced. The stability of both the liposome and the pharmaceutical agent is thus maintained, prior to administration. The pH gradient is, however, present when the liposome is administered in vivo because the quenching agent rapidly exits the liposome.
Techniques related to temporary setpoint values are disclosed. The techniques may involve causing operation of a fluid delivery device in a first mode for automatically delivering fluid to a patient based on a first target glucose value. Additionally, the techniques may involve obtaining a second target glucose value. The second target glucose value may be a temporary target glucose value to be used for a specified period of time to regulate fluid delivery to the patient, and the second target glucose value may be greater than the first target glucose value. The techniques may further involve causing, based on obtaining the second target glucose value, operation of the fluid delivery device in a second mode for automatically delivering fluid to the patient. The second mode may be for reduced fluid delivery during the specified period of time.
Glycolipids of branched chain alkyl oligosaccharides according to this patent comprise of a primary alcohol branched in the 2-position and an oligosaccharide, covalently bond to the alcohol in either a- or ss-linkage (shown in Formula I and Formula II). These compounds show particularly interesting phase behavior not found for the corresponding straight chain counterparts. The properties involve an ambient temperature liquid crystalline appearance and thermotropic liquid crystal phase polymorphism. Upon the latter, the formation of cubic phases is considered most interesting with respect to life science applications, e.g. liposome for drug delivery. Depending on the choice of sugar head group and alkyl tail, various levels of water miscibility may be adjusted to meet applications requirements (complete solubility for emulsifier applications, e.g. cosmetic creams, to limited water swelling only, e.g. for the preparation of artificial membranes). The closed structural relationship to natural lipids also make branched chain alkyl oligosaccharides valuable subjects for biochemical investigations, e.g. membrane studies. The range of possible applications for glycolipids of branched chain alkyl oligosaccharides involve material science liquid crystal applications, e.g. optical switches, as well as surfactants and the life science applications (see above).
Focal cortical dysplasia (FCD) represents the most common cause of drug-resistant epilepsy in adult and pediatric surgical series. However, genetic factors contributing to severe phenotypes of FCD remain unknown. We present a patient with an exceptionally rapid development of drug-resistant epilepsy evolving in super-refractory status epilepticus. We performed multiple clinical (serial EEG, MRI), biochemical (metabolic and immunological screening), genetic (WES from blood- and brain-derived DNA), and histopathological investigations. The patient presented 1 month after an uncomplicated varicella infection. MRI was negative, as well as other biochemical and immunological examinations. Whole-exome sequencing of blood-derived DNA detected a heterozygous paternally inherited variant NM_006267.4(RANBP2):c.5233A>G p.(Ile1745Val) (Chr2[GRCh37]:g.109382228A>G), a gene associated with a susceptibility to infection-induced acute necrotizing encephalopathy. No combination of anti-seizure medication led to a sustained seizure freedom and the patient warranted induction of propofol anesthesia with high-dose intravenous midazolam and continuous respiratory support that however failed to abort seizure activity. Brain biopsy revealed FCD type IIa; this finding led to the indication of an emergency right-sided hemispherotomy that rendered the patient temporarily seizure-free. Postsurgically, he remains on antiseizure medication and experiences rare nondisabling seizures. This report highlights a uniquely severe clinical course of FCD putatively modified by the RANBP2 variant. PLAIN LANGUAGE SUMMARY: We report a case summary of a patient who came to our attention for epilepsy that could not be controlled with medication. His clinical course progressed rapidly to life-threatening status epilepticus with other unusual neurological findings. Therefore, we decided to surgically remove a piece of brain tissue in order to clarify the diagnosis that showed features of a structural brain abnormality associated with severe epilepsy, the focal cortical dysplasia. Later, a genetic variant in a gene associated with another condition, was found, and we hypothesize that this genetic variant could have contributed to this severe clinical course of our patient.
PURPOSE:To obtain garlic water having excellent flavor by heating a garlic, destroying alliinase, preparing garlic hot water from the resultant garlic, then charging parched unpolished rice into the aforementioned garlic hot water and eliminating malodor of the garlic. CONSTITUTION:A raw garlic is heated to destroy most of alliinase. The heat- treated garlic is then used to prepare garlic hot water. Parched unpolished rice is subsequently charged into the garlic hot water to eliminate malodor of the garlic and impart excellent flavor of the parched unpolished rice to the garlic hot water. Thereby, the objective flavored garlic water is produced. The resultant flavored garlic water is capable of holding intact effects of the garlic and effective in preventing diseases, etc., without emitting the malodor of the garlic from human bodies even in continuous drinking thereof for several years.
In a clinical metabolic inhibition study, a 3.8-fold increase in silodosin maximum plasma concentrations and 3.2-fold increase in silodosin exposure were observed with concurrent administration of a strong CYP3A4 inhibitor, 400 mg ketoconazole. Use of strong CYP3A4 inhibitors such as itraconazole or ritonavir may cause plasma concentrations of silodosin to increase. Concomitant administration of strong CYP3A4 inhibitors and RAPAFLO is contraindicated [see Contraindications (4), Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].

The effect of moderate CYP3A4 inhibitors on the pharmacokinetics of silodosin has not been evaluated. Concomitant administration with moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) may increase concentration of RAPAFLO. Exercise caution and monitor patients for adverse events when co-administering RAPAFLO with moderate CYP3A4 inhibitors.
The invention discloses a traditional Chinese medicine composition for treating blood-heat type atrophied fetus. The traditional Chinese medicine composition is characterized by being prepared from, by weight, 4 parts of deerhorn glue, 10 parts of bamboo shavings, 10 parts of tubeflower viburnum herb, 20 parts of bigleaf stonecrop herb, 20 parts of gynura bicolor (Roxb.) DC., 10 parts of radix adenophorae, 30 parts of clerodendron petasites (Lour.) Moore [C. viscosum Vent.], 20 parts of herba dendrobii loddigesii, 10 parts of mistletoe, 20 parts of ramie, 5 parts of amomum xanthioides, 20 parts of twigs and leaves of Tibet lyonia, 3 parts of mountain wood, 10 parts of dens draconis, 5 parts of sibirica walking fern herb and 6 parts of liquorice. The traditional Chinese medicine composition is used for treating the blood-heat type atrophied fetus and is high in effective rate, reliable in curative effect and capable of greatly lowering the perinatal mortality rate of fetuses.
Flow-Mediated Dilation (FMD) - Subjects will lie in the supine position for 20 minutes to obtain hemodynamic steady state. A blood pressure cuff (Hokanson) will be placed around the forearm (distal to the Doppler transducer) and rapidly inflated to 250 mmHg for 5 minutes (circulatory arrest). Simultaneous ultrasound images of the vessel (B-mode) and Doppler waveforms will be collected 10 seconds prior to and for 2 minutes following deflation of the cuff. All B-mode images will be analyzed using automated edge detection software (Medical Imaging Applications), while intensity weighted velocity spectra segments will be saved to the GE Logiq 7 hard drive for off-line blood velocity waveform analysis. P.I. has utilized the traditional method of brachial artery flow-mediated dilation (FMD) induced by reactive hyperemia to assess vascular endothelial function in populations ranging from young healthy adults to older adults with pathological conditions.

Spygmocor - Pulse Wave Velocity (PWV) - A Spygmocor® device will be used at baseline and following each protocol to assess PWV. PWV analysis provides a non-invasive assessment of arterial stiffness. Increased arterial stiffness is known to be associated with cardiovascular disease. The participant is required to lie in a resting position for approximately 30-45 minutes. The research assistant will place ECG electrode sensors at the carotid, femoral, radial and distal artery locations. A highly sensitive pen-like device, called a tonometer, is then gently applied to record the velocity of the blood flow between each of the points.
The International Classification of Health, Function, and Disability (ICF), developed by the World Health Organization, provides a standard framework for identifying the body functions and structures, activity restrictions, and difficulties in children's participation. One of the major innovations in the ICF is that it introduces an environmental factor classification that enables the identification of environmental barriers and facilitators for both the capacity and performance of activities and tasks in daily life. The physical, social, and behavioral environments in which humans live are shaped by environmental factors. Environmental factors are external to the individual and can have a positive or negative impact on an individual's participation, performance, and body function/structure.

One of the tools that evaluate the environmental home environment is the Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS). The AHEMD-IS is a valuable tool for assessing the home environment, one of the environmental factors affecting infant motor development, and is of considerable research and clinical importance. The importance of this questionnaire is based on evidence not just for the impact of the home environment on motor development, but also on future cognitive and social behaviors. Consequently, this study aimed to translate the original English version into Turkish and to test its psychometric properties for use in children aged 3-18 months. It was aimed to determine whether the translated questionnaire meets the appropriate and necessary standards for measuring the quantity and quality of motor competencies in the home environment of children aged 3-18 month.
Sepsis causes dysfunction in different organs, but the pathophysiological mechanisms behind it are similar and mainly involve complex hemodynamic and cellular dysfunction. The importance of microcirculatory dysfunction in sepsis is becoming increasingly evident, in which endothelial dysfunction and glycocalyx degradation play a major role. This study aimed to investigate the effects of hydrogen-rich saline (HRS) on renal microcirculation in septic renal failure, and whether Sirt1 was involved in the renoprotective effects of HRS. Rats model of sepsis was established by cecal ligation and puncture, and septic rats were intraperitoneal injected with HRS (10 mL/kg). We found that in sepsis, the degree of glycocalyx shedding was directly proportional to the severity of sepsis. The seven-day survival rate of rats in the HRS+CLP group (70%) was higher than that of the CLP group (30%). HRS improved acidosis and renal function and reduced the release of inflammatory factors (TNF, IL-1β, and IL-6). The endothelial glycocalyx of capillaries in the HRS+CLP group (115 nm) was observed to be significantly thicker than that in the CLP group (44 nm) and EX527 (67.2 nm) groups by electron microscopy, and fewer glycocalyx metabolites (SDC-1, HS, HA, and MMP9) were found in the blood. Compared with the CLP group, HRS reduced renal apoptosis and upregulated Sirt1 expression, and inhibited the NF-κB/MMP9 signaling pathway. In addition, HRS did not damage immune function in septic rats as well. Generally speaking, our results suggest that HRS can alleviate the inflammatory response, inhibit glycocalyx shedding, improve septic kidney injury, and enhance survival rate.
Dysregulated circular RNAs (circRNAs) are significantly related with tumor initiation and progression. However, biological activity and potential molecular mechanism of circRNAs in gastric cancer (GC) deserve further exploration. We carried out total RNA sequencing and acquired the expression profiles of circRNAs. Quantitative real-time PCR as well as RNA in situ hybridization helped to validate circ_0000119 dysregulation. Various in vitro experiments were utilized to investigate the biological activities of circ_0000119 in GC, and the clinical relation of circ_0000119 in vivo was identified through nude mouse xenograft models. Finally, the molecular mechanism of circ_0000119 was clarified via luciferase assays, western blot, and rescue experiments. Compared with adjacent normal tissues, the study found an increase in the expression of circ_0000119 as well as its host linear gene MAN1A2 in GC tissues. Circ_0000119 overexpression promoted proliferation and migration of GC cells in vitro and in vivo, whereas circ_0000119 suppression had the opposite effect. Mechanistically, circ_0000119 sponged miR-502-5p which played an inhibitory role in tumors. Furthermore, we found that miR-502-5p alleviated GC progression through targeting MTBP and downregulating its expression at mRNA and protein levels. In conclusion, our findings reveal a new regulatory mechanism for circ_0000119, which sponges the miR-502-5p, suppresses MTBP expression, and finally promotes GC progression.
The present invention relates to a traditional Chinese medicine preparation for curing coronary disease ventricular tachyarrhythmia and a preparation technological method thereof. The present invention is characterized in that the traditional Chinese medicine preparation is a dark brown solid, dark brown powder or dark brown physic liquor prepared from medicinal materials which comprise ginseng, ophiopogon root, curcuma root, angelica, prepared liauorice root, notoginseng, lightyellow sophora root and cassia twig. The traditional Chinese medicine preparation comprises hot water extracts of the ginseng, the ophiopogon root, the curcuma root, the angelica, the prepared liauorice root, the notoginseng, the ightyellow sophora root and the cassia twig and ethanol extracts of the ginseng and the notoginseng at normal temperature. The technological method comprises the following preparation processes of chop fine, ethanol extraction at normal temperature, water extraction through heating, filtration, deposition, pressure reduction concentration, vacuum drying at low temperature, solid powder preparation and capsule powder filling. The present invention provides the traditional Chinese medicine preparation for curing coronary disease ventricular tachyarrhythmia and the technological method for preparing the traditional Chinese medicine preparation for curing coronary disease ventricular tachyarrhythmia. Through the indication of animal experiments and clinical tests, the traditional Chinese medicine preparation has the advantages of accurate curative effect, reliable pharmacologicalmechanism and no toxic and side effect.
EFUDEX Topical Solutions and Cream are topical preparations containing the fluorinated pyrimidine 5-fluorouracil, an antineoplastic antimetabolite.

EFUDEX Topical Solution consists of 2% or 5% fluorouracil on a weight/weight basis, compounded with disodium edetate, hydroxypropyl cellulose, methylparaben, propylene glycol, propylparaben, and tris (hydroxymethyl) aminomethane.

EFUDEX Cream contains 5% fluorouracil in a vanishing cream base consisting of methylparaben, polysorbate 60, propylene glycol, propylparaben, purified water, stearyl alcohol, and white petrolatum.

Chemically, fluorouracil is a 5-fluoro-2,4(1H,3H)-pyrimidinedione. It is a white to practically white crystalline powder which is sparingly soluble in water and slightly soluble in alcohol. One gram of fluorouracil is soluble in 100 mL of propylene glycol. The molecular weight of 5-fluorouracil is 130.08 and the structural formula is:
Methods for reducing MSK1 levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III. Methods for inhibiting MSK1 serine 376  phosphorylation in a plurality of cells are also disclosed, which include providing to the cells a curcumin composition that is at least 5% curcumin III. In addition, methods for ameliorating inflammation in a subject are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. Still further, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. In addition, compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier.
Epirubicin Hydrochloride Injection, USP is an anthracycline cytotoxic agent, intended for intravenous administration. Epirubicin hydrochloride is supplied as a sterile, clear, red solution and is available in glass vials containing 50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride. Inactive ingredients include sodium chloride, and water for injection. The pH of the solution has been adjusted to 3.0 with hydrochloric acid.

Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic derivative of daunorubicin. The chemical name is (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy- -L-arabino-hexopyranoside hydrochloride. The active ingredient is a red-orange hygroscopic powder, with the molecular formula C27H29NO11•HCl and a molecular weight of 579.98.

The structural formula is as follows:
A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
Pleural effusions are common in patients recovering from cardiac surgery. Symptomatic patients with pleural effusions complain of shortness of breath, cough, chest pain and are more hypoxic and tachypneic. Clinically significant effusions can slow recovery in the hospital and beyond, and are a critical source of hospital readmissions after discharge. It is not well characterized how this impacts hospital outcomes. Further it is unknown if the effusions themselves are associated with impaired outcomes, or if pleural effusions simply arise in more complicated, older patients, thus suggesting the impaired outcomes are the result of coexisting morbidities. To better understand the impact of this complication and to address the question mentioned before, this study was carried out to determine the clinical and economic outcomes of pleural effusions in propensity-matched patients during early recovery from cardiac surgery. To compare patient groups with and without pleural effusion, the following baseline characteristics were used: e.g. age, sex, body-mass-index, priority of surgery, type of surgery, duration of surgery, APACHE II Score of patients on admission in the ICU.
This study is a longitudinal, randomized control trial evaluating the use of two commercially available dynamic arm support devices (1) Armon Ayura-Kinova and 2) JAECO WREX) to promote participation in activities of daily living (ADLs) in non-ambulatory individuals with Duchenne muscular dystrophy (DMD) with upper extremity weakness. Up to 30 individuals will be enrolled to participate in this research study, which includes a two-week baseline data collection period, a four-week device trial and a two-week post device data collection period. Participants will be randomly assigned to trial one of the dynamic arm support devices during the four week in-home trial. The ActiGraph GT9x (name of device), a wrist worn activity monitoring device, will be worn during the baseline period, the device trial and the post device data collection period to capture upper extremity (UE) movement patterns. UE performance will be further quantified with use of a physical motor assessment, the Performance of Upper Limb (PUL) assessment and patient reported outcomes. Data gleaned will provide important knowledge and objective results regarding the potential benefit of dynamic arm supports in individuals with DMD with limited functional use of their upper extremities.
It has been discovered that any RNA can be targeted for cleavage by RNase P from prokaryotic or eukaryotic cells using a suitably designed oligonucleotide ("external guide sequence", or EGS) to form a hybrid with the target RNA, thereby creating a substrate for cleavage by RNase P in vitro. The EGS hydrogen bonds to the targeted RNA to form a partial tRNA like structure including the aminoacyl acceptor stem, the T stem and loop, and part of the D stem. An EGS can be modified both by changes in sequence and by chemical modifications to the nucleotides. The EGS can be a separate molecule or can be combined with an RNase P catalytic RNA sequence to form a single oligonucleotide molecule ("RNase P internal guide sequence" or RIGS). Methods are also disclosed to randomly select and to express a suitable EGS or RIGS in vivo to make a selected RNA a target for cleavage by a host cell RNase P or introduced RIGS, thus preventing expression of the function of the target RNA. The methods and compositions should be useful to prevent the expression of disease- or disorder-causing genes in vivo.
PURPOSE: To provide an oral composition that reduces formation of tartar on teeth and contains, as active ingredients, a polymer, e.g. a poly (α- hydroxyacrylic acid) as well as phosphate, sulfate and alkoxy derivative thereof in combination with a carrier. CONSTITUTION: This new agent for reducing tartar is obtained by formulating an effective amount of a polymer [poly(α-hydroxyacrylic acid) is particularly suitable] for preventing tartar formation represented by the formula (R1 and R2 are each H and an alkyl; R3 is H, phosphate, sulfate and an alkyl; M is H, an alkali metal, an alkaline earth metal, an ammonium, etc.; x is 3-10,000) with an effective amount of a carrier such as water, glycerol, sorbitol, etc. The dentifrice composition is a mixture of these medicines. Further, a fluoride ion source containing fluoride ion in a concentration of about 25-3500ppm may be formulated to this composition.